Desvenlafaxine to relieve shingles (herpes zoster) pain
Official title: The Analgesic Efficacy and Safety of Oral Medications (Desvenlafaxine) in Patients With Herpes Zoster
Run by Beijing Tiantan Hospital · NCT07361809 · Data updated 2026-11-12
This trial will test whether adding desvenlafaxine to standard treatment helps adults with recent shingles reduce moderate to severe pain.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 750 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | December 15, 2025 |
| Main results expected | September 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT07361809 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with shingles rash onset under 90 days, average pain score of at least 4 on an NRS, acceptable liver and kidney tests, and ability to consent are the intended participants.
✕Probably not a fit
Patients with disseminated or ocular shingles, prior desvenlafaxine use, known intolerance to the drug, or significant organ dysfunction are unlikely to benefit from joining this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with shingles that began within the past 90 days and who report moderate to severe pain will receive either desvenlafaxine plus conventional therapy or conventional therapy alone. Liver and kidney function limits are applied and prior use of desvenlafaxine or hypersensitivity excludes participation. Pain severity is measured using a numeric rating scale, and safety events will be monitored during the treatment period. The goal is to see if increasing serotonin and norepinephrine availability with desvenlafaxine provides better pain relief without substantially more adverse events.
Why it matters
Potential benefit: If successful, this could provide better pain relief for acute shingles and might reduce the chance of developing long-term postherpetic neuralgia.
How similar studies have gone: Other SNRIs have shown benefit for some types of neuropathic pain, but desvenlafaxine specifically for herpes zoster pain is relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Ages more than 18 years; * 2\. Patients with onset of HZ rash less than 90 days; * 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain); * 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal; * 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher; * 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements. Exclusion Criteria: * 1\. History of taking desvenlafaxine; * 2\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ; * 3\. History of intolerance or hypersensitivity to any active components or excipient of the desvenlafaxine; * 4\. History of systemic immune diseases, organ transplantation, or cancers; * 5\. Pregnancy or breastfeeding; * 6\. Suffering from acute or chronic pain disorders other than HZ.
Where it's running
-
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China Recruiting
Study contacts
- Study coordinator: Fang Luo
- Email: 13611326978@163.com
- Phone: 13611326978
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+
A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.
-
How long the live shingles vaccine protects you
This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.
-
Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.
This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.
-
Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia
This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.
-
Lyophilized shingles mRNA vaccine safety and immune response
This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.
-
Loxoprofen patch for relieving shingles pain
This will test if adding a loxoprofen sodium patch to standard care reduces pain in adults with shingles.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.